PR
OCUL icon

PSP Research’s Ocular Therapeutix OCUL Stock Holding History

PSP Research’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Hold
15,000
– – 0.08% 72
2026
Q1 		$127K Sell
15,000
-27,853
-65% -$265K 0.09% 79
2025
Q4 		$520K Buy
+42,853
New +$521K 0.45% 65

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PSP Research's OCUL Position: Q2 2026 in Review

PSP Research held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 15,000 shares worth $147K. The position accounts for 0.08% of the portfolio, ranked #72.

PSP Research first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. The position peaked at $520K in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • PSP Research held 15,000 shares of Ocular Therapeutix worth $147K as of Q2 2026.
  • PSP Research left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up 0.08% of PSP Research's portfolio in Q2 2026, its #72 holding.
  • PSP Research first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Ocular Therapeutix position peaked at $520K in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.